Clinic
United Memorial Medical Center
United Memorial Medical Center was paid $25.45M by Medicaid between Jan 2018 and Dec 2024, across 266 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 15% of everything it billed.
33Billing provider infoUNITED MEMORIAL MEDICAL CENTER
BATAVIA, NY 14020
BATAVIA, NY 14020
33aNPI1902800352assigned 06/13/2005
33bProvider typeUrgent Care Clinic/Center
28Total paid$25.45M
24GClaims508,901
24DCodes billed266
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in New York
Rank by total paid#9 of 138
Median peer was paid$576K
This provider vs. median44×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 569 | $85K | |
| 2019 | 22,401 | $997K | |
| 2020 | 71,379 | $3.27M | |
| 2021 | 94,853 | $4.71M | |
| 2022 | 108,590 | $5.51M | |
| 2023 | 117,447 | $5.91M | |
| 2024incomplete | 93,662 | $4.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 37,661 | 32,351 | $3.87M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.1% | 22,982 | 21,043 | $2.32M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 12,192 | 11,666 | $1.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 9,385 | 8,525 | $1.39M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.4% | 6,500 | 5,726 | $1.38M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.0% | 9,433 | 8,615 | $1.28M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 913 | 907 | $729K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 2,123 | 2,097 | $671K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.3% | 301 | 300 | $580K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 1,635 | 1,595 | $477K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 1,343 | 1,324 | $423K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 3,072 | 3,016 | $421K |
254 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 9,028 | $415K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 478 | $394K |
| 80053 | Comprehensive metabolic panel | 1.5% | 26,234 | $387K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 2,838 | $384K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.4% | 1,221 | $345K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 1,903 | $341K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 853 | $329K |
| 59025 | Fetal non-stress test | 1.2% | 1,931 | $317K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 2,411 | $273K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.0% | 6,017 | $267K |
| 87631 | 1.0% | 3,275 | $259K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.0% | 4,347 | $256K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,440 | $252K |
| 20610 | <1% | 973 | $220K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 698 | $215K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,306 | $208K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,667 | $204K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,658 | $170K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,684 | $169K |
| 93975 | <1% | 632 | $162K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,682 | $158K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 187 | $156K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,184 | $153K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 420 | $137K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,721 | $136K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,786 | $128K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,178 | $126K |
| 97161 | <1% | 1,297 | $108K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,225 | $105K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,822 | $101K |
| 76801 | <1% | 1,124 | $101K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,048 | $98K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 466 | $97K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,157 | $96K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,855 | $89K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,080 | $85K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,569 | $83K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,683 | $82K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,658 | $78K |
| 80061 | Lipid panel | <1% | 9,249 | $77K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,263 | $67K |
| 76830 | Ultrasound, transvaginal | <1% | 485 | $65K |
| 74018 | <1% | 1,244 | $58K | |
| 73564 | <1% | 1,159 | $57K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 520 | $55K |
| 76770 | <1% | 296 | $55K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,327 | $53K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,292 | $51K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 490 | $49K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,024 | $47K |
| 73610 | <1% | 1,339 | $46K | |
| 87660 | <1% | 4,476 | $44K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 435 | $44K |
| 87634 | <1% | 1,343 | $44K | |
| 90715 | <1% | 1,589 | $44K | |
| 73030 | <1% | 1,051 | $42K | |
| 73630 | <1% | 1,257 | $40K | |
| 84702 | <1% | 5,159 | $37K | |
| 87480 | <1% | 4,252 | $37K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 326 | $36K |
| 87510 | <1% | 4,209 | $36K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 70 | $36K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,972 | $35K |
| 84484 | <1% | 6,795 | $35K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 40 | $34K |
| 86850 | <1% | 2,022 | $33K | |
| 76536 | <1% | 279 | $33K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 734 | $33K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,282 | $33K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 342 | $32K |
| 73100 | <1% | 663 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,741 | $29K |
| 84439 | <1% | 3,759 | $27K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $27K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 232 | $26K |
| 82607 | <1% | 2,544 | $26K | |
| 90686 | <1% | 1,122 | $25K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,157 | $24K |
| 82728 | <1% | 2,341 | $23K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 118 | $22K |
| 86780 | <1% | 2,297 | $22K | |
| 86803 | <1% | 2,588 | $22K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 225 | $22K |
| 87150 | <1% | 753 | $22K | |
| 86900 | <1% | 1,958 | $21K | |
| 73502 | <1% | 481 | $20K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 226 | $19K |
| 81025 | <1% | 4,315 | $19K | |
| 86901 | <1% | 1,967 | $19K | |
| 83655 | <1% | 1,500 | $17K | |
| 83690 | <1% | 5,480 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,495 | $17K |
| 85027 | <1% | 5,000 | $17K | |
| 83880 | <1% | 566 | $16K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 107 | $16K |
| 87070 | <1% | 2,267 | $16K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 280 | $14K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 26 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,123 | $14K |
| 87340 | <1% | 1,751 | $13K | |
| 73130 | <1% | 426 | $13K | |
| 86762 | <1% | 1,085 | $12K | |
| 96376 | <1% | 729 | $12K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $12K |
| 83550 | <1% | 2,388 | $11K | |
| 83735 | <1% | 3,245 | $11K | |
| 85610 | <1% | 3,059 | $11K | |
| 90677 | <1% | 251 | $11K | |
| 83540 | <1% | 2,571 | $11K | |
| 87081 | <1% | 2,824 | $10K | |
| 87040 | <1% | 2,237 | $10K | |
| 87186 | <1% | 1,920 | $9K | |
| 72100 | <1% | 163 | $9K | |
| 84403 | <1% | 403 | $9K | |
| 81001 | <1% | 5,192 | $9K | |
| 93971 | <1% | 72 | $8K | |
| 73560 | <1% | 296 | $8K | |
| 76813 | <1% | 120 | $8K | |
| 73110 | <1% | 253 | $8K | |
| 82784 | <1% | 648 | $7K | |
| 83605 | <1% | 1,616 | $7K | |
| 82570 | <1% | 1,889 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 112 | $7K |
| 87077 | <1% | 1,270 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 53 | $7K |
| 80076 | <1% | 870 | $7K | |
| 82803 | <1% | 238 | $7K | |
| 73140 | <1% | 217 | $7K | |
| 82746 | <1% | 694 | $6K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 494 | $6K |
| 82043 | <1% | 1,458 | $6K | |
| 86140 | <1% | 1,881 | $6K | |
| 88142 | <1% | 245 | $6K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 549 | $6K |
| 76641 | <1% | 24 | $5K | |
| 73120 | <1% | 122 | $5K | |
| 84153 | <1% | 401 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 43 | $5K |
| 99385 | <1% | 56 | $5K | |
| 85379 | <1% | 1,028 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 563 | $4K |
| 81003 | <1% | 4,149 | $4K | |
| 87430 | <1% | 826 | $4K | |
| 87088 | <1% | 756 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,168 | $4K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 536 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,362 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 36 | $4K |
| 85730 | <1% | 1,197 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 25 | $4K |
| 90651 | <1% | 73 | $4K | |
| 86706 | <1% | 468 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 188 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $4K |
| 97162 | <1% | 40 | $4K | |
| 90656 | <1% | 172 | $4K | |
| 86038 | <1% | 578 | $3K | |
| 84402 | <1% | 149 | $3K | |
| 85652 | <1% | 1,982 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 56 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 724 | $3K |
| 84481 | <1% | 278 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 494 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 363 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 679 | $3K |
| G0008 | Administration of influenza virus vaccine | <1% | 187 | $2K |
| 86704 | <1% | 262 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 78 | $2K |
| 86376 | <1% | 166 | $2K | |
| 82950 | <1% | 526 | $2K | |
| 73080 | <1% | 34 | $2K | |
| 83970 | <1% | 52 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 77 | $2K |
| 83001 | <1% | 125 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,794 | $2K |
| 84480 | <1% | 271 | $2K | |
| 87641 | <1% | 66 | $2K | |
| 99442 | <1% | 159 | $2K | |
| 88342 | <1% | 12 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,767 | $2K |
| 90680 | <1% | 56 | $1K | |
| 73590 | <1% | 32 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,021 | $1K |
| 86481 | <1% | 24 | $1K | |
| 82550 | <1% | 378 | $1K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 14 | $1K |
| 83002 | <1% | 76 | $1K | |
| 99173 | <1% | 595 | $1K | |
| 86696 | <1% | 83 | $1K | |
| 84550 | <1% | 338 | $1K | |
| 72110 | <1% | 24 | $1K | |
| 90697 | <1% | 38 | $996.94 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,088 | $990.77 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,661 | $947.79 |
| 86141 | <1% | 95 | $911.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 39 | $883.58 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 118 | $874.63 |
| 83520 | <1% | 112 | $843.22 | |
| 87147 | <1% | 359 | $810.88 | |
| 86431 | <1% | 201 | $810.15 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 89 | $803.81 |
| 81002 | <1% | 1,164 | $747.41 | |
| 84703 | <1% | 212 | $746.86 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 354 | $726.53 |
| 90734 | <1% | 56 | $702.80 | |
| 84146 | <1% | 40 | $702.28 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $660.96 |
| 87205 | <1% | 280 | $652.39 | |
| 90633 | <1% | 30 | $627.50 | |
| 99441 | <1% | 79 | $586.24 | |
| 82947 | <1% | 310 | $533.04 | |
| 84100 | <1% | 162 | $511.34 | |
| 88304 | <1% | 16 | $508.42 | |
| 86308 | <1% | 193 | $481.76 | |
| 97010 | <1% | 41 | $476.90 | |
| 96161 | <1% | 12 | $475.44 | |
| 80305 | <1% | 527 | $420.11 | |
| 83525 | <1% | 43 | $412.16 | |
| 86705 | <1% | 49 | $400.08 | |
| 86618 | <1% | 36 | $390.53 | |
| 84436 | <1% | 67 | $363.41 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 992 | $359.51 |
| 86800 | <1% | 25 | $311.06 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 97 | $310.04 |
| 90619 | <1% | 15 | $301.20 | |
| 80074 | <1% | 13 | $293.37 | |
| 86709 | <1% | 59 | $281.33 | |
| 86592 | <1% | 55 | $182.45 | |
| 82248 | <1% | 43 | $179.07 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 62 | $160.41 |
| 82150 | <1% | 65 | $157.48 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 26 | $134.16 |
| 83993 | <1% | 12 | $125.55 | |
| 99443 | <1% | 15 | $120.56 | |
| 83615 | <1% | 26 | $111.55 | |
| 86765 | <1% | 12 | $109.72 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 560 | $105.88 |
| 87449 | <1% | 24 | $105.54 | |
| 87272 | <1% | 12 | $102.06 | |
| 96127 | <1% | 17 | $75.85 | |
| 73562 | <1% | 12 | $75.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 198 | $69.46 |
| 84156 | <1% | 31 | $61.79 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 64 | $39.18 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 72 | $35.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 112 | $29.50 |
| 85018 | <1% | 25 | $26.67 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 12 | $4.83 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 18 | $3.56 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 17 | $2.87 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 67 | $0.36 |
| 99177 | 0% | 25 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 109 | $0.00 |
| A9270 | Non-covered item or service | 0% | 575 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGLASTONBURY, HOWARD (CFO)